Paradigm Biopharmaceuticals Ltd. appointed Helen Fisher to its Board as Non-Executive Director and Chair of the Audit and Risk Committee. Paradigm continues to progress toward submission of the IND for Zilosul® and focus on implementation of the OA clinical program to support commercialisation. Effective 23rd of February 2021, Paradigm is delighted to welcome Helen to the Board. Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte's life sciences practice in Australia for 5 years, having had many years' experience in the life sciences and health care sector.